Katrine Bosley

Katrine Bosley is the Chief Executive Officer of Editas Medicine. She has been part of the biotechnology industry for 25 years and has worked on innovative medicines across many different modalities (small molecules, biologics, vaccines, gene editing) and many different diseases (cancer, rheumatoid arthritis, Alzheimer's disease, multiple sclerosis, rare genetic diseases, Hepatitis C, et al). Katrine was recently the Entrepreneur-in-Residence at The Broad Institute, a biomedical and genomic research center, and prior to that, she was the CEO of Avila Therapeutics (acquired by Celgene). Earlier, she was Vice President, Business Development at Adnexus Therapeutics and then Vice President, Strategic Operations after Adnexus’ acquisition by Bristol-Myers Squibb. Katrine also held several positions at Biogen in business development, commercial operations, and portfolio strategy and was part of the healthcare team at the venture firm Highland Capital Partners. She is a graduate of Cornell University. In addition to her role at Editas, Katrine currently serves as Chairman of the Board of Genocea Biosciences (NASDAQ: GNCA) and is a Board member of Galapagos NV (EURONEXT and NASDAQ: GLPG), of Scholar Rock, LLC, and of BIO – the Biotechnology Industry Organization – and she is a review committee member for the Translation Fund of the Wellcome Trust.